TOT BIOPHARM International (HKG:1875) reported a net profit attributable to the equity holders of 35.4 million yuan for the nine months ended Sept. 30, compared with a loss of 32.4 million yuan in the corresponding period of the previous year, according to a Tuesday filing with the Hong Kong Stock Exchange.

The company's revenue was 809.0 million yuan, compared with 542.0 million yuan in the previous year period.

The company's shares were down about 6% in the recent trading.